Lilly has invested billions of dollars to ramp up production capacity.Eli Lilly (LLY -1.74%) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs. Lilly sells the compound tirzepatide under two different names -- Mounjaro for type 2 diabetes and Zepbound for weight loss. But doctors have prescribed either for the weight loss indication. These drugs have become blockbusters, bringing in mor ...

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024.LONDON — U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.The weight-loss treatment firm and creator of Zepbound announced Monday that it would commit £279 million ($364 million) to help tackle Britain's significant health challenges — including obesity.The "strategic collaboration," agreed with the ...

文章核心观点 - 新数据显示,与使用 ustekinumab 相比,更多接受 mirikizumab 治疗的中重度活动性克罕病患者在第52周实现了组织学缓解 [1][2] - 这是首次在克罕病临床试验中报告使用系统评估五个肠段(四个结肠和一个回肠)的组织学和联合组织学-内窥镜结果,符合欧洲克罕病和结肠炎学会(ECCO)最新发布的黏膜组织病理学声明 [1][4] - 这些数据进一步证实了 mirikizumab 在帮助克罕病患者实现更深层次的黏膜愈合方面的潜力 [2] 关键要点总结 1. 组织学缓解 - 在VIVID-1试验中,与安慰剂相比,mirikizumab在第12周和第52周均显示在所有组织学和组织学-内窥镜终点上均有名义上的统计学显著改善 [2] - 在整体人群中,第52周时接受 mirikizumab 治疗的患者中有更多人实现了组织学缓解(58.2%比48.8%;p=0.0075) [2] - 在基线时有活跃性组织学疾病且至少有1次生物制剂治疗失败的患者中,mirikizumab也显示在第52周有更高的组织学缓解率(56.5%比41.3%;p=0.0064)和内窥镜-组织学缓解率(39.6%比27.8%;p=0.024) [2] 2. 安全性 - mirikizumab在中重度活跃性克罕病患者中的总体安全性与在溃疡性结肠炎患者中的已知安全性一致 [3] - 严重不良事件的发生率在安慰剂组高于 mirikizumab 组 [3] - 最常见的不良事件包括COVID-19、贫血、关节痛、头痛、上呼吸道感染、鼻咽炎和注射部位反应 [3] 3. 监管进展 - 礼来已在全球范围内(包括美国、欧洲、日本和中国)提交了 mirikizumab 用于治疗克罕病的上市申请,并计划进行更多全球监管提交 [4] - 礼来正在研究 mirikizumab 在儿童和成人克罕病患者中的长期疗效和安全性 [5] 4. 其他适应症 - mirikizumab 已获批用于治疗成人中重度活跃性溃疡性结肠炎,商品名为 Omvoh [6][15] - 礼来正在进行多项 mirikizumab 在溃疡性结肠炎适应症的临床试验,包括儿童患者和成人长期疗效及安全性研究 [6]

These stocks look like slam-dunk picks for growth investors.October sometimes gets a bad rap from investors. Sure, several major stock market crashes have occurred during the month in the past. However, October has actually been a pretty good month for stocks historically. Three Fool.com contributors have identified what they believe are no-brainer growth stocks to buy in October. Here's why they picked Eli Lilly (LLY 2.35%), Novo Nordisk (NVO 2.14%), and Vertex Pharmaceuticals (VRTX 1.17%).A plethora of gr ...

Eli Lilly and Company TodayLLYEli Lilly and Company$932.06 +21.37 (+2.35%) 52-Week Range$547.61▼$972.53Dividend Yield0.56%P/E Ratio114.79Price Target$979.29Add to WatchlistIn a year and a half, Eli Lilly NYSE: LLY has roughly doubled in value. It is now the most valuable pharmaceutical company in the world. It took that mantle from the long-held dominance by Johnson and Johnson NYSE: JNJ back in May of 2023 and hasn’t looked back since. However, much of that increase in value has come due to multiple expans ...

The latest trading session saw Eli Lilly (LLY) ending at $910.69, denoting a -0.98% adjustment from its last day's close. This move lagged the S&P 500's daily loss of 0.21%. Meanwhile, the Dow lost 0.14%, and the Nasdaq, a tech-heavy index, lost 0.05%.Shares of the drugmaker witnessed a loss of 0.12% over the previous month, beating the performance of the Medical sector with its loss of 3.28% and underperforming the S&P 500's gain of 5.94%.The upcoming earnings release of Eli Lilly will be of great interest ...

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.Dividend-paying stocks have been dominant performers in the U.S. market since 1900. Their power lies in compounding, which can substantially increase returns over time.Companies that consistently raise their dividends frequently outperform the S&P 500 over long periods. These dividend growers often feature strong fundamentals, proven business models, and management teams focused on shareholder ret ...

Eli Lilly's (LLY, Financial) stock experienced a notable movement, rising 1.71% to a price of $913.72. This surge was driven by the Congressional Budget Office (CBO) report on the potential impact if Medicare were to cover anti-obesity medications, including Eli Lilly's weight loss drug, Zepbound.The CBO estimates this Medicare coverage could increase federal spending by $35 billion from 2026 to 2034, underscoring the significant sales potential for GLP-1 drugs in the weight loss market. Investors have resp ...

The pharmaceutical giant's weight loss medication Zepbound was in the spotlight again Tuesday.Most investors are aware of the vast sales potential for the effective new weight loss treatments known as GLP-1 drugs, and the market for them is still relatively quite young. On Tuesday, the Congressional Budget Office (CBO) put a number on one piece of that market's potential. As that figure was large, weight loss drug producer Eli Lilly (LLY 1.70%) saw a nearly 2% bump in its share price in response. That compa ...

 SAN CARLOS, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Qinotto, Inc., a central nervous system (CNS) focused biopharmaceutical company that is discovering novel vehicles to deliver large molecule therapeutics to the brain, announced today that it has entered a research collaboration and license agreement with Eli Lilly and Company (Lilly) to discover next-generation antibody-based vehicles for brain transport. Under this collaboration agreement, Qinotto will partner with Lilly Catalyze360-ExploR&D (https:// ...